Literature DB >> 18981171

Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase.

Peter I Mackenzie1, Anne Rogers, Joanna Treloar, Bo R Jorgensen, John O Miners, Robyn Meech.   

Abstract

The UDP glycosyltransferases (UGT) attach sugar residues to small lipophilic chemicals to alter their biological properties and enhance elimination. Of the four families present in mammals, two families, UGT1 and UGT2, use UDP glucuronic acid to glucuronidate bilirubin, steroids, bile acids, drugs, and many other endogenous chemicals and xenobiotics. UGT8, in contrast, uses UDP galactose to galactosidate ceramide, an important step in the synthesis of glycosphingolipids and cerebrosides. The function of the fourth family, UGT3, is unknown. Here we report the cloning, expression, and functional characterization of UGT3A1. This enzyme catalyzes the transfer of N-acetylglucosamine from UDP N-acetylglucosamine to ursodeoxycholic acid (3alpha, 7beta-dihydroxy-5beta-cholanoic acid). The enzyme uses ursodeoxycholic acid and UDP N-acetylglucosamine in preference to other primary and secondary bile acids, and other UDP sugars such as UDP glucose, UDP glucuronic acid, UDP galactose, and UDP xylose. In addition to ursodeoxycholic acid, UGT3A1 has activity toward 17alpha-estradiol, 17beta-estradiol, and the prototypic substrates of the UGT1 and UGT2 forms, 4-nitrophenol and 1-naphthol. A polymorphic UGT3A1 variant containing a C121G substitution was catalytically inactive. UGT3A1 is found in the liver and kidney, and to a lesser, in the gastrointestinal tract. These data describe the first characterization of a member of the UGT3 family. Its activity and distribution suggest that UGT3A1 may have an important role in the metabolism and elimination of ursodeoxycholic acid in therapies for ameliorating the symptoms of cholestasis or for dissolving gallstones.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981171      PMCID: PMC2662294          DOI: 10.1074/jbc.M807961200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Acyl glucuronidation and glucosidation of a new and selective endothelin ET(A) receptor antagonist in human liver microsomes.

Authors:  Cuyue Tang; Jerome H Hochman; Bennett Ma; Raju Subramanian; Kamlesh P Vyas
Journal:  Drug Metab Dispos       Date:  2003-01       Impact factor: 3.922

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Bile acid N-acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7 beta-hydroxylated bile acids in humans.

Authors:  H U Marschall; H Matern; H Wietholtz; B Egestad; S Matern; J Sjövall
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

4.  Bile acid N-acetylglucosaminides. Formation by microsomal N-acetylglucosaminyltransferases in human liver and kidney.

Authors:  H Matern; R Bolz; H U Marschall; J Sjövall; S Matern
Journal:  FEBS Lett       Date:  1990-09-17       Impact factor: 4.124

5.  Hepatic and extrahepatic glucuronidation of bile acids in man. Characterization of bile acid uridine 5'-diphosphate-glucuronosyltransferase in hepatic, renal, and intestinal microsomes.

Authors:  S Matern; H Matern; E H Farthmann; W Gerok
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

6.  A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini.

Authors:  J K Ritter; F Chen; Y Y Sheen; H M Tran; S Kimura; M T Yeatman; I S Owens
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

Review 7.  Drug glucuronidation in humans.

Authors:  J O Miners; P I Mackenzie
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

8.  The glucuronidation of hydroxylated metabolites of benzo[a]pyrene and 2-acetylaminofluorene by cDNA-expressed human UDP-glucuronosyltransferases.

Authors:  C J Jin; J O Miners; B Burchell; P I Mackenzie
Journal:  Carcinogenesis       Date:  1993-12       Impact factor: 4.944

Review 9.  Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.

Authors:  Gustav Paumgartner; Ulrich Beuers
Journal:  Clin Liver Dis       Date:  2004-02       Impact factor: 6.126

10.  Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7.

Authors:  Peter Mackenzie; Joanna M Little; Anna Radominska-Pandya
Journal:  Biochem Pharmacol       Date:  2003-02-01       Impact factor: 5.858

View more
  22 in total

1.  Use of glucuronidation fingerprinting to describe and predict mono- and dihydroxyflavone metabolism by recombinant UGT isoforms and human intestinal and liver microsomes.

Authors:  Lan Tang; Ling Ye; Rashim Singh; Baojian Wu; Chang Lv; Jie Zhao; Zhongqiu Liu; Ming Hu
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

2.  Quantitative profiling of the UGT transcriptome in human drug-metabolizing tissues.

Authors:  A Tourancheau; M Rouleau; S Guauque-Olarte; L Villeneuve; I Gilbert; A Droit; C Guillemette
Journal:  Pharmacogenomics J       Date:  2017-04-25       Impact factor: 3.550

3.  Identification of residues that confer sugar selectivity to UDP-glycosyltransferase 3A (UGT3A) enzymes.

Authors:  Robyn Meech; Anne Rogers; Lizhe Zhuang; Benjamin C Lewis; John O Miners; Peter I Mackenzie
Journal:  J Biol Chem       Date:  2012-05-23       Impact factor: 5.157

Review 4.  Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.

Authors:  Upendra A Argikar; Philip M Potter; J Matthew Hutzler; Punit H Marathe
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

5.  Identification of Two Sulfated Cholesterol Metabolites Found in the Urine of a Patient with Niemann-Pick Disease Type C as Novel Candidate Diagnostic Markers.

Authors:  Masamitsu Maekawa; Kaoru Omura; Shoutaro Sekiguchi; Takashi Iida; Daisuke Saigusa; Hiroaki Yamaguchi; Nariyasu Mano
Journal:  Mass Spectrom (Tokyo)       Date:  2016-11-25

6.  Alterations in hepatic mRNA expression of phase II enzymes and xenobiotic transporters after targeted disruption of hepatocyte nuclear factor 4 alpha.

Authors:  Hong Lu; Frank J Gonzalez; Curtis Klaassen
Journal:  Toxicol Sci       Date:  2010-10-08       Impact factor: 4.849

7.  RNA-sequencing quantification of hepatic ontogeny and tissue distribution of mRNAs of phase II enzymes in mice.

Authors:  Hong Lu; Sumedha Gunewardena; Julia Y Cui; Byunggil Yoo; Xiao-bo Zhong; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2013-02-04       Impact factor: 3.922

8.  Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites.

Authors:  Jin Zhou; Timothy S Tracy; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2009-12-09       Impact factor: 3.922

9.  Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3.

Authors:  Nina Sneitz; Michael H Court; Xiuling Zhang; Kaisa Laajanen; Karen K Yee; Pamela Dalton; Xinxin Ding; Moshe Finel
Journal:  Pharmacogenet Genomics       Date:  2009-12       Impact factor: 2.089

Review 10.  Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans.

Authors:  Ryoichi Fujiwara; Emiko Yoda; Robert H Tukey
Journal:  Drug Metab Pharmacokinet       Date:  2017-10-07       Impact factor: 3.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.